U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07342491) titled 'Trial of the ACTG (Advancing Clinical Therapeutics Globally for HIV and Other Infections)' on Jan. 13.
Brief Summary: This study will test if the medicine dasatinib can lower the hidden amount of HIV in the body, called the HIV "reservoir." It will also check if dasatinib is safe and easy to take for people living with HIV who have a suppressed viral load while on antiretroviral therapy (ART). Adults 18 years or older who have been on ART for at least 48 months and have had a suppressed HIV-1 viral load for at least 36 months may be able to join.
People will be randomly assigned to take dasatinib 100 mg by mouth once a day or a loo...